David Nutt

51.1k total citations · 13 hit papers
701 papers, 33.7k citations indexed

About

David Nutt is a scholar working on Cellular and Molecular Neuroscience, Experimental and Cognitive Psychology and Pharmacology. According to data from OpenAlex, David Nutt has authored 701 papers receiving a total of 33.7k indexed citations (citations by other indexed papers that have themselves been cited), including 253 papers in Cellular and Molecular Neuroscience, 157 papers in Experimental and Cognitive Psychology and 137 papers in Pharmacology. Recurrent topics in David Nutt's work include Neuroscience and Neuropharmacology Research (135 papers), Neurotransmitter Receptor Influence on Behavior (130 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (114 papers). David Nutt is often cited by papers focused on Neuroscience and Neuropharmacology Research (135 papers), Neurotransmitter Receptor Influence on Behavior (130 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (114 papers). David Nutt collaborates with scholars based in United Kingdom, United States and Netherlands. David Nutt's co-authors include Leslie A. King, David Erritzøe, Robin Carhart‐Harris, Lawrence D. Phillips, Anne Lingford‐Hughes, Sue Wilson, Andrea L. Malizia, Philip J. Cowen, Louise M. Paterson and Caroline Bell and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

David Nutt

683 papers receiving 32.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function

2006 1.1k citations David Nutt et al. profile →
Drug harms in the UK: a multicriteria decision analysis

2010 1.0k citations David Nutt, Lawrence D. Phillips et al. profile →
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

2016 1.0k citations Robin Carhart‐Harris, Mark Bolstridge et al. profile →
Development of a rational scale to assess the harm of drugs of potential misuse

2007 819 citations David Nutt et al. profile →
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

2012 737 citations Robin Carhart‐Harris, David Erritzøe et al. profile →
Sleep disorders as core symptoms of depression

2008 577 citations David Nutt, Sue Wilson et al. profile →
Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

2014 429 citations David S. Baldwin, David Nutt et al. Journal of Psychopharmacology profile →
Homological scaffolds of brain functional networks

2014 389 citations Robin Carhart‐Harris, David Nutt et al. profile →
The dopamine theory of addiction: 40 years of highs and lows

2015 389 citations David Nutt, Anne Lingford‐Hughes et al. profile →
Amphetamine, past and present – a pharmacological and clinical perspective

2013 385 citations David Nutt et al. Journal of Psychopharmacology profile →
Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution

2016 315 citations Enzo Tagliazucchi, Leor Roseman et al. profile →
Increased global integration in the brain after psilocybin therapy for depression

2022 257 citations Christopher Timmermann, Matthew B. Wall et al. profile →
Human brain effects of DMT assessed via EEG-fMRI

2023 105 citations Christopher Timmermann, Leor Roseman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Nutt United Kingdom	91	11.1k	8.3k	6.0k	5.7k	5.2k	701	33.7k
Philip J. Cowen United Kingdom	87	8.3k 0.7×	4.1k 0.5×	7.9k 1.3×	3.8k 0.7×	6.5k 1.3×	608	29.2k
Dennis L. Murphy United States	104	17.3k 1.6×	9.5k 1.2×	7.1k 1.2×	9.8k 1.7×	4.1k 0.8×	572	40.9k
Joanna S. Fowler United States	115	19.3k 1.7×	5.4k 0.7×	13.0k 2.2×	9.2k 1.6×	2.9k 0.6×	477	47.3k
Guy M. Goodwin United Kingdom	100	4.6k 0.4×	6.7k 0.8×	9.0k 1.5×	2.0k 0.4×	6.6k 1.3×	476	35.0k
Harriet de Wit United States	82	12.9k 1.2×	5.9k 0.7×	7.5k 1.2×	4.1k 0.7×	4.3k 0.8×	427	28.4k
J. John Mann United States	104	9.6k 0.9×	15.8k 1.9×	6.6k 1.1×	7.1k 1.2×	4.3k 0.8×	640	47.3k
Robert M. Post United States	106	6.9k 0.6×	6.6k 0.8×	7.0k 1.2×	3.0k 0.5×	3.4k 0.7×	586	37.3k
Siegfried Kasper Austria	91	5.1k 0.5×	5.0k 0.6×	5.6k 0.9×	4.6k 0.8×	6.3k 1.2×	1.0k	34.8k
John M. Kane United States	118	4.9k 0.4×	9.8k 1.2×	6.0k 1.0×	4.0k 0.7×	3.9k 0.8×	928	52.6k
Ross J. Baldessarini United States	93	5.4k 0.5×	6.4k 0.8×	2.7k 0.4×	3.8k 0.7×	1.8k 0.4×	618	30.1k

Countries citing papers authored by David Nutt

Since Specialization

Citations

This map shows the geographic impact of David Nutt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Nutt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Nutt more than expected).

Fields of papers citing papers by David Nutt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Nutt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Nutt. The network helps show where David Nutt may publish in the future.

Co-authorship network of co-authors of David Nutt

This figure shows the co-authorship network connecting the top 25 collaborators of David Nutt. A scholar is included among the top collaborators of David Nutt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Nutt. David Nutt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Perl, Yonatan Sanz, Carla Pallavicini, Gustavo Deco, et al.. (2025). Transient destabilization of whole brain dynamics induced by N,N-Dimethyltryptamine (DMT). Communications Biology. 8(1). 409–409.

Jones, I., et al.. (2025). Searching for the Puerperal Trigger: Molecular Genetic Studies of Bipolar Affective Puerperal Psychosis. Psychopharmacology Bulletin. 40(2). 115–125. 1 indexed citations

Cardone, Paolo, Charlotte Martial, Yonatan Sanz Perl, et al.. (2025). A Virtual Clinical Trial of Psychedelics to Treat Patients With Disorders of Consciousness. Advanced Science. 13(11). e11780–e11780.

Turton, Samuel, Louise M. Paterson, James F. Myers, et al.. (2024). Exploratory study of associations between monetary reward anticipation brain responses and mu-opioid signalling in alcohol dependence, gambling disorder and healthy controls. SHILAP Revista de lepidopterología. 4(3). 100211–100211. 1 indexed citations

Belelli, Delia, Jeremy J. Lambert, Murphy Lam Yim Wan, et al.. (2024). From bugs to brain: unravelling the GABA signalling networks in the brain–gut–microbiome axis. Brain. 148(5). 1479–1506. 17 indexed citations

Zafar, Rayyan, Matthew B. Wall, David Nutt, & David Erritzøe. (2023). Validation of novel fMRI paradigms in gambling disorder. Neuroscience Applied. 2. 102829–102829.

Schlag, Anne Katrin, et al.. (2023). Cannabis-based medicinal products (CBMPs) for the treatment of Long COVID symptoms: current and potential applications. SHILAP Revista de lepidopterología. 487–503. 1 indexed citations

Jauhar, Sameer, Joseph Hayes, Guy M. Goodwin, et al.. (2019). Antidepressants, withdrawal, and addiction; where are we now?. Journal of Psychopharmacology. 33(6). 655–659. 19 indexed citations

Mick, Inge, John McGonigle, Mark Bolstridge, et al.. (2017). Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study. Biological Psychiatry. 81(11). 941–948. 27 indexed citations

10.

Amsterdam, Jan van, Lawrence D. Phillips, Graeme Henderson, et al.. (2015). Ranking the harm of non-medically used prescription opioids in the UK. Regulatory Toxicology and Pharmacology. 73(3). 999–1004. 16 indexed citations

11.

Korpi, Esa R., Bjørnar den Hollander, Usman Farooq, et al.. (2015). Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse. Pharmacological Reviews. 67(4). 872–1004. 110 indexed citations

12.

Zohar, Joseph, Stephen M. Stahl, Hans‐Jürgen Möller, et al.. (2015). A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. European Neuropsychopharmacology. 25(12). 2318–2325. 110 indexed citations

13.

Baldwin, David S., Katherine J. Aitchison, Alan N. Bateson, et al.. (2013). Benzodiazepines: Risks and benefits. A reconsideration. Journal of Psychopharmacology. 27(11). 967–971. 159 indexed citations

14.

Paterson, Louise M., Robin J. Tyacke, David Nutt, & Gitte M. Knudsen. (2010). Measuring Endogenous 5-HT Release by Emission Tomography: Promises and Pitfalls. Journal of Cerebral Blood Flow & Metabolism. 30(10). 1682–1706. 111 indexed citations

15.

Nutt, David. (2008). Relationship of neurotransmitters to the symptoms of major depressive disorder.. PubMed. 69 Suppl E1. 4–7. 340 indexed citations

16.

Paterson, Louise M., David Nutt, & Sue Wilson. (2008). NAPSAQ-1: National Patient Sleep Assessment Questionnaire in depression. International Journal of Psychiatry in Clinical Practice. 13(1). 48–58. 16 indexed citations

17.

Nutt, David, et al.. (2006). Generalized anxiety disorder: A comorbid disease. European Neuropsychopharmacology. 16. S109–S118. 71 indexed citations

18.

Robinson, Emma, David Nutt, Helen C. Jackson, & Alan L. Hudson. (2005). The uptake of a fluorescently labelled antisense oligonucleotide in vitro and in vivo. Journal of Neuroscience Methods. 147(1). 48–54. 2 indexed citations

19.

Argyropoulos, Spilios V., Jane Hicks, Jon Nash, et al.. (2003). Correlation of subjective and objective sleep measurements at different stages of the treatment of depression. Psychiatry Research. 120(2). 179–190. 97 indexed citations

20.

Wilson, Steven James, Caroline Bell, Nicholas J. Coupland, & David Nutt. (2000). Sleep changes during long-term treatment of depression with fluvoxamine - a home-based study. Psychopharmacology. 149(4). 360–365. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact